Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grape polyphenol concentrate is a dietary supplement derived from grapes, rich in bioactive polyphenolic compounds. It is being investigated for its potential to manage chronic systemic inflammation in patients with Type 1 Diabetes Mellitus (T1DM). The concentrate acts primarily by inhibiting the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, which is a central regulator of the inflammatory response to metabolic endotoxemia (e.g., lipopolysaccharides entering circulation from the gut). By suppressing this pathway and providing antioxidant effects, it reduces markers of systemic inflammation such as C-reactive protein (CRP). It is considered a non-pharmacological intervention to reduce cardiovascular risk and manage inflammatory complications in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on grape polyphenol concentrate.